Tony Ho compensation by year
CRISPR Therapeutics Summary Compensation Table · all 5 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Salary | $170,833 | $414,980 | $431,575 | $451,000 | $467,000 |
| Bonus | $100,000 | $0 | $0 | $0 | $0 |
| Stock awards | $1,267,500 | $0 | $3,333,900 | $614,213 | $1,204,920 |
| Option awards | $2,843,484 | $3,466,188 | $1,948,674 | $2,368,031 | $2,787,434 |
| Non-equity incentive | $92,199 | $258,321 | $281,603 | $288,189 | $210,150 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $9,625 | $9,800 | $168,811 | $1,854,139 |
| Total | $4,474,016 | $4,149,115 | $6,005,552 | $3,890,244 | $6,523,643 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CRISPR Therapeutics AG DEF 14A filed April 25, 2022, accession 0000950170-22-006098, and prior-year filings.
How this page was built: the CRISPR Therapeutics AG filed document, accession 0000950170-22-006098. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 13,333 | $1,010,375 | — |
| RSU | 9,167 | $694,675 | — |
| RSU | 9,000 | $682,020 | — |
| RSU | 3,334 | $252,651 | — |
| Option | 11,806 | — | $86.75 |
| Option | 13,225 | — | $97.00 |
| Option | 18,959 | — | $133.88 |
| Option | 3,313 | — | $51.49 |
| Option | 5,375 | — | $59.31 |
| Option | 23,438 | — | $40.87 |
| Option | 30,938 | — | $44.67 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CRISPR Therapeutics AG's FY2021 proxy; value at the fiscal year-end close, as the company printed it.
CRISPR Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | $17,037,015 |
| Brendan Smith | Former Chief Financial Officer | $7,345,040 |
| Tony Ho · this page | Former EVP, Research and Development | $6,523,643 |
| Lawrence Klein | Former Chief Operating Officer | $5,960,500 |
| James Kasinger | General Counsel | $4,642,761 |
| Michael Tomsicek | Former Chief Financial Officer | $3,760,766 |
The full CRISPR Therapeutics compensation record
free company briefThis page is one person within CRISPR Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CRISPR Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CRISPR Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.